THEO-260

AXP000056.1 · Oncolytic virus

Platform
adenovirus
Originator
Theolytics
Sponsor
Theolytics

Names

NameTypeSource
THEO-260preferred name, codecurator, ncit

Virus

Role
Oncolytic
Family
Adenoviridae
Virus
human adenovirus (serotype not reported)
Modifications
selected by directed evolution; replicates in cancer cells and cancer-associated fibroblasts
Route
intraperitoneal
Source
evidence

Cross-references

NCI Thesaurus
C222794

Approvals

No regulatory approval recorded.

Clinical trials (2)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07211659Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer PatientsRecruitingPhase 12026-02-132027-0918Ovarian Cancer
NCT06618235Trial of THEO-260 in Ovarian Cancer PatientsRecruitingPhase 1/22024-09-242028-0644Ovarian Cancer

Recent changes

No changes recorded in its trials yet.

Notes

Selected by directed evolution; replicates in cancer cells and in cancer-associated fibroblasts. First patient dosed November 2024 in the phase 1/2a OCTOPOD trial in ovarian cancer (intraperitoneal). Backbone serotype not stated in sources consulted.

How to cite

THEO-260 (AXP000056.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000056.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.